UMB Bank’s Cullinan Oncology CGEM Stock Holding History

UMB Bank’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.5K	Hold	685	–	–	﹤0.01%	1863
2026 Q1	$9.73K	Hold	685	–	–	﹤0.01%	1863
2025 Q4	$7.09K	Buy	+685	New	+$6.18K	﹤0.01%	1933

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UMB Bank's CGEM Position: Q2 2026 in Review

UMB Bank held its Cullinan Oncology (CGEM) position steady in Q2 2026 at 685 shares worth $12.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1863.

UMB Bank first reported a position in CGEM in Q4 2025 and has held it in 3 quarters since. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

UMB Bank held 685 shares of Cullinan Oncology worth $12.5K as of Q2 2026.
UMB Bank left its Cullinan Oncology share count unchanged in Q2 2026.
Cullinan Oncology made up ﹤0.01% of UMB Bank's portfolio in Q2 2026, its #1863 holding.
UMB Bank first reported a position in Cullinan Oncology in Q4 2025 and has held it in 3 quarters since.
184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on UMB Bank's 13F filing for Q2 2026, filed 13 Aug 2026.